ObjectivesQuality of life (QOL) is a multidimensional construct including emotional wellâbeing, life satisfaction, and physical health. Individuals with posttraumatic stress disorder (PTSD) consistently report low QOL, highlighting the importance of assessing the effectiveness of firstâline PTSD treatments (e.g., exposureâbased therapies) on QOL. This metaâanalysis examined the efficacy of exposure therapy for PTSD on QOL compared to control conditions (e.g., waitlist, medication, treatmentâasâusual) at posttreatment and followâup (ranging from 1 month to 2 years).MethodsBuilding on a previous metaâanalysis of exposureâbased therapy for PTSD, we searched PsycINFO and Medline in December 2021, July 2022, and March 2023 to include randomized controlled trials of exposureâbased treatments for adult PTSD assessing QOL. We screened 295 abstracts for initial eligibility; 20 articles met inclusion criteria and were included (Nâ=â2729 participants). Risk of bias was evaluated using the Cochrane Risk of Bias tool 2.0.ResultsAt posttreatment, exposureâbased therapies showed a medium effect on QOL relative to control conditions (kâ=â25, gâ=â0.67). This effect was not observed at followâup for the small subset of studies with followâup data (kâ=â8, gâ=â0.16). At posttreatment, effect size varied significantly as a function of the control condition (pâ<â.0001). There were no differences in QOL effects across exposure therapies at posttreatment or followâup (pâ=â.09).ConclusionExposure therapy was associated with greater improvement in QOL compared to control conditions at posttreatment. Exposure was not superior to control conditions at followâup, and the longerâterm impact of exposure on QOL is unclear. The implications of these findings are discussed, along with the need for more PTSD treatment studies to examine QOL outcomes at posttreatment and followâup.